Can a patient have near‑normal forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) but a markedly reduced diffusing capacity for carbon monoxide (TLCO) and transfer coefficient (KCO) around 33% of predicted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Yes, Near-Normal FEV1/FVC with Severely Reduced TLCO and KCO is a Well-Recognized Pattern

This pattern of preserved spirometry (normal FEV1 and FVC) with markedly reduced diffusing capacity (TLCO and KCO around 33%) is absolutely possible and represents isolated impairment of gas exchange without ventilatory defect. This dissociation between spirometry and diffusion capacity occurs in several important clinical conditions and should prompt specific diagnostic considerations.

Understanding the Physiological Dissociation

The key concept is that spirometry measures airflow and lung volumes, while TLCO/KCO assess the gas exchange surface area and alveolar-capillary membrane function—these are fundamentally different physiological processes 1. According to ERS guidelines, when spirometric parameters lie near normal limits but clinical suspicion exists, additional studies including DLCO should be performed 1.

Why This Pattern Occurs

  • TLCO reflects the product of KCO (transfer coefficient) and VA (alveolar volume) 2
  • Severely reduced TLCO/KCO indicates impaired gas exchange at the alveolar-capillary membrane level
  • Spirometry can remain normal when lung volumes are preserved but the functional gas exchange surface is compromised

Clinical Conditions Associated with This Pattern

Primary Considerations with Severely Reduced KCO (<40% predicted):

Pulmonary vascular disease is the most frequent association with severe KCO reduction 3:

  • Pulmonary hypertension (present in 44% of patients with KCO <40%) 3
  • Pre-capillary pulmonary hypertension accounts for 8% of severe KCO reduction cases 3
  • Systematic echocardiography is warranted when KCO is severely reduced 3

Early interstitial lung disease (28% of severe KCO reduction cases) 3:

  • In idiopathic pulmonary fibrosis, 78% of patients with normal FVC still have abnormal TLCO 4
  • A "normal" FVC should be viewed with caution as it is most often associated with abnormal TLCO 4
  • TLCO correlates better with disease severity than FVC in IPF 4

Emphysema (46% of severe KCO reduction cases) 3:

  • Destruction of alveolar-capillary surface area
  • Can present with preserved spirometry in early stages

Combined pulmonary fibrosis and emphysema (16% of cases) 3:

  • Opposing effects on lung volumes can "normalize" spirometry
  • Disproportionate pulmonary hypertension common (mean PAP >35 mmHg in 63% of cases) 3

Other Important Causes:

  • Pulmonary vascular involvement from systemic diseases
  • Anemia (reduces TLCO but typically not KCO to this degree)
  • Pulmonary Kaposi's sarcoma in HIV patients (all patients show reduced TLCO and KCO even with normal radiographs) 5
  • Post-heart transplant changes (mean TLCO decline of 14% predicted) 6

Critical Diagnostic Approach

Immediate Assessment:

  1. Echocardiography is mandatory with KCO <40% to assess for pulmonary hypertension 3

    • 88% of patients with severe KCO reduction have systolic PAP ≥35 mmHg 3
  2. High-resolution CT chest to evaluate for:

    • Interstitial lung disease patterns
    • Emphysema
    • Combined disease
    • Pulmonary vascular abnormalities
  3. Consider right heart catheterization if echocardiography suggests pulmonary hypertension 3

    • Particularly important as pulmonary hypertension may be disproportionate to parenchymal disease

Longitudinal Monitoring:

  • Serial TLCO measurements are more sensitive than spirometry for detecting disease progression 4
  • In IPF, only 1/3 of patients with FVC-based progression also had TLCO progression, but 2/3 with TLCO progression also had FVC progression 4
  • Progressive decline in KCO occurs even in asymptomatic HIV patients (median 7% over 9 months) 7

Common Pitfalls to Avoid

Do not dismiss normal spirometry as reassuring when clinical suspicion exists—TLCO provides critical additional information 1, 4.

Do not attribute isolated DLCO reduction to "deconditioning" without thorough evaluation—this pattern demands investigation for the conditions listed above 3.

Do not use VA from single-breath DLCO testing to assess restriction—it systematically underestimates TLC and should not be interpreted as demonstrating restrictive defect 1.

Recognize that both DLCO and KCO must be assessed together for proper interpretation—they provide complementary information about gas exchange 2.

Prognostic Implications

Severely reduced TLCO/KCO carries significant prognostic weight:

  • Physiological quotients for DLCO and KCO show superior discrimination for all-cause mortality compared to percent predicted or z-scores 8
  • In children born preterm, low KCO associates with higher pulmonary artery pressures and may identify those at risk for late cardiopulmonary disease 9
  • Baseline TLCO predicts outcomes in various conditions including heart transplantation 6

The combination of normal spirometry with TLCO/KCO at 33% predicted is clinically significant and requires systematic evaluation for pulmonary vascular disease, interstitial lung disease, or emphysema 3.

Related Questions

Why should we measure KCO (transfer coefficient for carbon monoxide) in addition to DLCO (diffusing capacity of the lung for carbon monoxide) rather than relying on DLCO alone?
Do these pulmonary function test results—forced expiratory volume in one second/forced vital capacity ratio 84%, forced expiratory volume in one second 112% of predicted, forced vital capacity 101% of predicted, total lung capacity 100% of predicted, residual volume/total lung capacity ratio 96%, and diffusing capacity of the lung for carbon monoxide 95% of predicted—indicate normal lung function, and what follow‑up is recommended?
What is the interpretation and recommended management for a patient with vital capacity (VC) 61% predicted, forced expiratory volume in one second (FEV1) 55% predicted, and diffusing capacity of the lung for carbon monoxide (TLCO) 39% predicted?
What do the lung function results (FEV1 55% predicted, vital capacity 62% predicted, total lung capacity 59% predicted) indicate?
What does an FEV1/FVC ratio of 72% with FEV1 57% predicted and FVC 60% predicted indicate in an obese never‑smoker?
Does Vyvanse (lisdexamfetamine) cause increased sweating?
What neurologic adverse effects can antidepressant medications cause?
What is the urgent treatment for a 9-year-old child with severe otalgia?
Can vitamin D decrease serum calcium levels?
Is there a nebulized formulation that combines budesonide, formoterol, and glycopyrrolate similar to the Breztri dry‑powder inhaler?
At what age should a smoker with a ≥30 pack‑year history begin low‑dose computed tomography screening for lung cancer?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.